SK609 HCl
CAS No. 1092797-77-7
SK609 HCl( —— )
Catalog No. M34027 CAS No. 1092797-77-7
SK609 HCl (SK609 hydrochloride) is a dopamine D3 receptor (D3R) selective agonist that inhibits norepinephrine transporter proteins and can be used to study Parkinson's disease and cognitive disorders.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 150 | In Stock |
|
| 10MG | 223 | In Stock |
|
| 25MG | 376 | In Stock |
|
| 50MG | 527 | In Stock |
|
| 100MG | 735 | In Stock |
|
| 200MG | 1014 | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameSK609 HCl
-
NoteResearch use only, not for human use.
-
Brief DescriptionSK609 HCl (SK609 hydrochloride) is a dopamine D3 receptor (D3R) selective agonist that inhibits norepinephrine transporter proteins and can be used to study Parkinson's disease and cognitive disorders.
-
DescriptionSK609 hydrochloride is a dopamine D3 receptor (D3R) selective agonist with an EC50 of 1109 nM. SK609 hydrochloride has the potential for parkinson research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayGPCR/G Protein
-
TargetDopamine Receptor
-
RecptorDopamine Receptor | Norepinephrine
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1092797-77-7
-
Formula Weight220.14
-
Molecular FormulaC10H15Cl2N
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESCl.ClC=1C=CC=CC1CCC(N)C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
-
Phenelzine
Phenelzine is an antidepressant and mania drug, which is a monoamine oxidase inhibitor. Its antidepressant effect is similar to that of niacinamide.
-
ONC206
ONC206 is an analogue of TRAIL inducer ONC201 and is a selective antagonist of the D2-like dopamine receptors (DRD2/3/4) at nanomolar concentrations. ONC206 also has broad-spectrum anti-tumor activity. ONC206 (Oncoceutics) is an imipiridone with nanomolar potency and analogue of ONC201, a selective dopamine receptor D2 (DRD2) antagonist currently being investigated in phase II clinical trials for serous endometrial cancer (SEC).??
-
LE 300
LE 300 represents a structurally novel type of antagonists acting preferentially at the dopamine D(1)/D(5)receptors and the serotonin 5-HT(2A)receptor.
Cart
sales@molnova.com